Antisense Oligonucleotides Market Outlook

The global antisense oligonucleotides market is projected to amass revenue of around US$ 5,519.6 million by 2033, up from US$ 2,913.5 million in 2023 moving forward with a CAGR of 6.6% during the forecast period.

The antisense oligonucleotides adoption trends are significantly swayed by their promising treatment options for a range of medical disorders. Moreover, they also facilitate the development of therapeutics affecting protein targets that cannot be treated with protein therapeutics, propelling the market growth. They target a particular malfunctioning gene, interfere with RNA function at the cellular level, and also be silenced or modulated and the same is catching the attention of market players.

The rising demand for antisense oligonucleotides is attributed to its aid in modifying the immune system that facilitates the treatment of a wide range of autoimmune disorders - that cannot be treated with available drugs.

It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies, spurring the adoption of antisense oligonucleotides.

Moreover, the market is enhanced by the minimal side effects of antisense oligonucleotides, which are controlled with ease as compared to other classes of drugs.

The antisense oligonucleotides sector has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 - which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016).

However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy.

However, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic causes of infant mortality with no approved treatments.

Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the market outlook is positively influenced by the leading players in the market and the amount of research and development investments.

Attributes Details
Antisense Oligonucleotides Market CAGR (2023 to 2033) 6.6%
Antisense Oligonucleotides Market Size (2023) US$ 2,913.5 million
Antisense Oligonucleotides Market Size (2033) US$ 5,519.6 million

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What Factors are Shaping the Antisense Oligonucleotides Industry?

A strong pipeline of antisense oligonucleotides and increased focus on a large number of product approvals and commercialization are likely to expand the global antisense oligonucleotides sector size.

Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level are further contributing to the growth of the global market.

However, the global antisense oligonucleotides business is grappling with numerous challenges related to the diversity of oligonucleotides, delivery, and regulatory complexity.

Despite several advancements at clinical levels, the delivery of active oligonucleotides to the actual site within target cells is still one of the key challenges hindering the growth of the global antisense oligonucleotides sector. In addition to this, developing a new set of unique regulatory guidelines is also expected to hamper the market statistics.

Regional Analysis

Countries Market Share (2022)
United States 58%
Germany 3.3%
Japan 2.9%

Why is North America Expected to Dominate the Antisense Oligonucleotides Industry?

North America clearly dominates the global antisense oligonucleotides industry due to a strong product pipeline and an increasing number of FDA approvals in the region, contributing to the region’s market share of 60.9% in 2022.

For instance, the international biotechnology company Biogen Inc.'s Nusinersen, sold as Spinraza, received FDA approval in the USA in 2018. Health infrastructures and an increase in the use of oligonucleotides in the development of innovative pharmacological therapies are additional factors driving market expansion.

What are the Growth Prospects for the Europe Antisense Oligonucleotides Business?

In 2022, the Europe antisense oligonucleotides sector captured a share of 14.3%. In order to improve their product portfolio for antisense oligonucleotides, key players in Europe are concentrating on strategic mergers and acquisitions, in turn spurring the market growth in Europe.

For instance, in 2014, the multinational pharmaceutical and biopharmaceutical company AstraZeneca Plc. merged with the pharmaceutical firm Ionis Pharmaceuticals. Additionally, it is anticipated that a strong pipeline of important companies aids the market growth to some level.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How is the Start-up Ecosystem in the Antisense Oligonucleotides Industry?

While many organizations are working on RNA-based treatments and vaccines, including well-known companies like Pfizer, BioNtech, Moderna, etc., a few biotech start-ups are also emerging, shaping the market trends.

Examples:

  • RNA-targeting biopharmaceuticals are being created by the USA-based start-up Arrakis Therapeutics.

The company's tiny molecule medications bind to targets that were previously believed to be unreachable as well as those that were confirmed using genetic and pharmacological techniques.

These medications use multiple ways to either decrease RNA translation or splicing. Drugs for oncology, dyslipidemia, and uncommon disorders are in the startup's development.

  • Antisense RNA therapies are created by the Spanish start-up ARTHEx Biotech for hereditary illnesses.

The company's top therapeutic candidate for type 1 myotonic dystrophy is an anti-microRNA (DM1). The start-up's anti-miRs are shown to suppress microRNAs that repress MBNL1/2 genes in DM1 in muscle biopsies of patients.

How Strong Is the Competition in the Antisense Oligonucleotides Business?

The market for antisense oligonucleotides is fairly consolidated, with a few competitors gaining a significant growing share. The market participants for antisense oligonucleotides are heavily invested in research and development. These activities assist the participants in developing novel formulations that are advantageous to the user.

A couple of recent developments are:

  • AmpTec, a renowned German company that specializes in mRNA contract development and manufacture, was purchased by MilliporeSigma (USA) (CDMO).

The agreement improves MilliporeSigma's capacity to produce and develop mRNA for its clients' usage in Covid-19 and numerous other diseases-related vaccines, therapies, and diagnostics.

  • oPools- oligo pools, a collection of 350-nucleotide-long, high-quality DNA oligonucleotides, was introduced by Integrated DNA Technology (USA).

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Key player

  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Biogen
  • Alnylam Pharmaceuticals, Inc.
  • Antisense Therapeutics Limited
  • Isarna Therapeutics GmbH
  • Arrowhead Pharmaceuticals, Inc.
  • Atlantic Pharmaceuticals, Inc.
  • Enzon Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • Gene Signal International SA
  • GlaxoSmithKline plc
  • Geron Corporation
  • Grades
  • ICO Therapeutics
  • Aptose Biosciences
  • Marina Biotech
  • miRagen Therapeutics, Inc.
  • Synlogic, Inc.
  • OncoGenex Pharmaceuticals Inc.
  • Pharmaxis Ltd, Regulus Therapeutics Inc.
  • Rexahn Pharmaceuticals, Inc.
  • RXi Pharmaceuticals

Key Segments

By Drug:

  • Approved Drugs
  • Pegaptanib
  • Mipomersen
  • Eteplirsen
  • Pipeline Analysis

By Indication:

  • Ocular Diseases
  • Cancer
  • Diabetes
  • Amyotrophic Lateral Sclerosis (ALS)
  • Duchenne Muscular Dystrophy
  • Spinal Muscular Atrophy
  • Others

By Application:

  • Basic Research
  • Genomics
  • Target Validation
  • Drug Discovery

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • The Middle East and Africa
  • Europe

Frequently Asked Questions

Why is North America Emerging as an Opportunistic Market?

Robust product pipeline and rising FDA approvals in the region dominate the market.

What is the Lucrative Opportunity in the Market?

The rising number of FDA approvals is the key opportunity in the market.

What is the Key Trend of the Market?

Advanced pharmacological techniques are the key trend.

What Drives Sales of the Market?

Promising treatment offers for medical disorders.

What is the Growth Forecast for the Market?

The market is forecast to register a CAGR of 6.6% through 2033.

Table of Content
1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033
        5.3.1. Approved Drugs
        5.3.2. Pegaptanib
        5.3.3. Mipomersen
        5.3.4. Eteplirsen
        5.3.5. Pipeline Analysis
    5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
        6.3.1. Ocular Diseases
        6.3.2. Cancer
        6.3.3. Diabetes
        6.3.4. Amyotrophic Lateral Sclerosis (ALS)
        6.3.5. Duchenne Muscular Dystrophy
        6.3.6. Spinal Muscular Atrophy
        6.3.7. Others
    6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Application , 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application , 2023 to 2033
        7.3.1. Basic Research
        7.3.2. Genomics
        7.3.3. Target Validation
        7.3.4. Drug Discovery
    7.4. Y-o-Y Growth Trend Analysis By Application , 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By Application , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Western Europe
        8.3.4. Eastern Europe
        8.3.5. South Asia and Pacific
        8.3.6. East Asia
        8.3.7. Middle East and Africa
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        9.2.1. By Country
            9.2.1.1. USA.
            9.2.1.2. Canada
        9.2.2. By Drug
        9.2.3. By Indication
        9.2.4. By Application
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Drug
        9.3.3. By Indication
        9.3.4. By Application
    9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Drug
        10.2.3. By Indication
        10.2.4. By Application
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Drug
        10.3.3. By Indication
        10.3.4. By Application
    10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. United Kingdom.
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Western Europe
        11.2.2. By Drug
        11.2.3. By Indication
        11.2.4. By Application
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Drug
        11.3.3. By Indication
        11.3.4. By Application
    11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. Poland
            12.2.1.2. Russia
            12.2.1.3. Czech Republic
            12.2.1.4. Romania
            12.2.1.5. Rest of Eastern Europe
        12.2.2. By Drug
        12.2.3. By Indication
        12.2.4. By Application
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Drug
        12.3.3. By Indication
        12.3.4. By Application
    12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. India
            13.2.1.2. Bangladesh
            13.2.1.3. Australia
            13.2.1.4. New Zealand
            13.2.1.5. Rest of South Asia and Pacific
        13.2.2. By Drug
        13.2.3. By Indication
        13.2.4. By Application
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Drug
        13.3.3. By Indication
        13.3.4. By Application
    13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. Japan
            14.2.1.3. South Korea
        14.2.2. By Drug
        14.2.3. By Indication
        14.2.4. By Application
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Drug
        14.3.3. By Indication
        14.3.4. By Application
    14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of MEA
        15.2.2. By Drug
        15.2.3. By Indication
        15.2.4. By Application
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Drug
        15.3.3. By Indication
        15.3.4. By Application
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA.
        16.1.1. Pricing Analysis
        16.1.2. Market Share Analysis, 2022
            16.1.2.1. By Drug
            16.1.2.2. By Indication
            16.1.2.3. By Application
    16.2. Canada
        16.2.1. Pricing Analysis
        16.2.2. Market Share Analysis, 2022
            16.2.2.1. By Drug
            16.2.2.2. By Indication
            16.2.2.3. By Application
    16.3. Brazil
        16.3.1. Pricing Analysis
        16.3.2. Market Share Analysis, 2022
            16.3.2.1. By Drug
            16.3.2.2. By Indication
            16.3.2.3. By Application
    16.4. Mexico
        16.4.1. Pricing Analysis
        16.4.2. Market Share Analysis, 2022
            16.4.2.1. By Drug
            16.4.2.2. By Indication
            16.4.2.3. By Application
    16.5. Germany
        16.5.1. Pricing Analysis
        16.5.2. Market Share Analysis, 2022
            16.5.2.1. By Drug
            16.5.2.2. By Indication
            16.5.2.3. By Application
    16.6. United Kingdom.
        16.6.1. Pricing Analysis
        16.6.2. Market Share Analysis, 2022
            16.6.2.1. By Drug
            16.6.2.2. By Indication
            16.6.2.3. By Application
    16.7. France
        16.7.1. Pricing Analysis
        16.7.2. Market Share Analysis, 2022
            16.7.2.1. By Drug
            16.7.2.2. By Indication
            16.7.2.3. By Application
    16.8. Spain
        16.8.1. Pricing Analysis
        16.8.2. Market Share Analysis, 2022
            16.8.2.1. By Drug
            16.8.2.2. By Indication
            16.8.2.3. By Application
    16.9. Italy
        16.9.1. Pricing Analysis
        16.9.2. Market Share Analysis, 2022
            16.9.2.1. By Drug
            16.9.2.2. By Indication
            16.9.2.3. By Application
    16.10. Poland
        16.10.1. Pricing Analysis
        16.10.2. Market Share Analysis, 2022
            16.10.2.1. By Drug
            16.10.2.2. By Indication
            16.10.2.3. By Application
    16.11. Russia
        16.11.1. Pricing Analysis
        16.11.2. Market Share Analysis, 2022
            16.11.2.1. By Drug
            16.11.2.2. By Indication
            16.11.2.3. By Application
    16.12. Czech Republic
        16.12.1. Pricing Analysis
        16.12.2. Market Share Analysis, 2022
            16.12.2.1. By Drug
            16.12.2.2. By Indication
            16.12.2.3. By Application
    16.13. Romania
        16.13.1. Pricing Analysis
        16.13.2. Market Share Analysis, 2022
            16.13.2.1. By Drug
            16.13.2.2. By Indication
            16.13.2.3. By Application
    16.14. India
        16.14.1. Pricing Analysis
        16.14.2. Market Share Analysis, 2022
            16.14.2.1. By Drug
            16.14.2.2. By Indication
            16.14.2.3. By Application
    16.15. Bangladesh
        16.15.1. Pricing Analysis
        16.15.2. Market Share Analysis, 2022
            16.15.2.1. By Drug
            16.15.2.2. By Indication
            16.15.2.3. By Application
    16.16. Australia
        16.16.1. Pricing Analysis
        16.16.2. Market Share Analysis, 2022
            16.16.2.1. By Drug
            16.16.2.2. By Indication
            16.16.2.3. By Application
    16.17. New Zealand
        16.17.1. Pricing Analysis
        16.17.2. Market Share Analysis, 2022
            16.17.2.1. By Drug
            16.17.2.2. By Indication
            16.17.2.3. By Application
    16.18. China
        16.18.1. Pricing Analysis
        16.18.2. Market Share Analysis, 2022
            16.18.2.1. By Drug
            16.18.2.2. By Indication
            16.18.2.3. By Application
    16.19. Japan
        16.19.1. Pricing Analysis
        16.19.2. Market Share Analysis, 2022
            16.19.2.1. By Drug
            16.19.2.2. By Indication
            16.19.2.3. By Application
    16.20. South Korea
        16.20.1. Pricing Analysis
        16.20.2. Market Share Analysis, 2022
            16.20.2.1. By Drug
            16.20.2.2. By Indication
            16.20.2.3. By Application
    16.21. GCC Countries
        16.21.1. Pricing Analysis
        16.21.2. Market Share Analysis, 2022
            16.21.2.1. By Drug
            16.21.2.2. By Indication
            16.21.2.3. By Application
    16.22. South Africa
        16.22.1. Pricing Analysis
        16.22.2. Market Share Analysis, 2022
            16.22.2.1. By Drug
            16.22.2.2. By Indication
            16.22.2.3. By Application
    16.23. Israel
        16.23.1. Pricing Analysis
        16.23.2. Market Share Analysis, 2022
            16.23.2.1. By Drug
            16.23.2.2. By Indication
            16.23.2.3. By Application
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Drug
        17.3.3. By Indication
        17.3.4. By Application
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. Ionis Pharmaceuticals, Inc.
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
        18.1.2. Sarepta Therapeutics
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
        18.1.3. Biogen
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
        18.1.4. Alnylam Pharmaceuticals, Inc.
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
        18.1.5. Antisense Therapeutics Limited
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
        18.1.6. Isarna Therapeutics GmbH
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
        18.1.7. Arrowhead Pharmaceuticals, Inc.
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
        18.1.8. Alantic Pharmaceuticals, Inc.
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
        18.1.9. Enzon Pharmaceuticals, Inc.
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
        18.1.10. Bio-Path Holdings, Inc.
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
        18.1.11. Gene Signal International SA
            18.1.11.1. Overview
            18.1.11.2. Product Portfolio
            18.1.11.3. Profitability by Market Segments
            18.1.11.4. Sales Footprint
            18.1.11.5. Strategy Overview
                18.1.11.5.1. Marketing Strategy
        18.1.12. GlaxoSmithKline plc
            18.1.12.1. Overview
            18.1.12.2. Product Portfolio
            18.1.12.3. Profitability by Market Segments
            18.1.12.4. Sales Footprint
            18.1.12.5. Strategy Overview
                18.1.12.5.1. Marketing Strategy
        18.1.13. Geron Corporation
            18.1.13.1. Overview
            18.1.13.2. Product Portfolio
            18.1.13.3. Profitability by Market Segments
            18.1.13.4. Sales Footprint
            18.1.13.5. Strategy Overview
                18.1.13.5.1. Marketing Strategy
        18.1.14. Grades
            18.1.14.1. Overview
            18.1.14.2. Product Portfolio
            18.1.14.3. Profitability by Market Segments
            18.1.14.4. Sales Footprint
            18.1.14.5. Strategy Overview
                18.1.14.5.1. Marketing Strategy
        18.1.15. ICO Therapeutics
            18.1.15.1. Overview
            18.1.15.2. Product Portfolio
            18.1.15.3. Profitability by Market Segments
            18.1.15.4. Sales Footprint
            18.1.15.5. Strategy Overview
                18.1.15.5.1. Marketing Strategy
        18.1.16. Aptose Biosciences
            18.1.16.1. Overview
            18.1.16.2. Product Portfolio
            18.1.16.3. Profitability by Market Segments
            18.1.16.4. Sales Footprint
            18.1.16.5. Strategy Overview
                18.1.16.5.1. Marketing Strategy
        18.1.17. Marina Biotech
            18.1.17.1. Overview
            18.1.17.2. Product Portfolio
            18.1.17.3. Profitability by Market Segments
            18.1.17.4. Sales Footprint
            18.1.17.5. Strategy Overview
                18.1.17.5.1. Marketing Strategy
        18.1.18. miRagen Therapeutics, Inc.
            18.1.18.1. Overview
            18.1.18.2. Product Portfolio
            18.1.18.3. Profitability by Market Segments
            18.1.18.4. Sales Footprint
            18.1.18.5. Strategy Overview
                18.1.18.5.1. Marketing Strategy
        18.1.19. Synlogic, Inc.
            18.1.19.1. Overview
            18.1.19.2. Product Portfolio
            18.1.19.3. Profitability by Market Segments
            18.1.19.4. Sales Footprint
            18.1.19.5. Strategy Overview
                18.1.19.5.1. Marketing Strategy
        18.1.20. OncoGenex Pharmaceuticals Inc.
            18.1.20.1. Overview
            18.1.20.2. Product Portfolio
            18.1.20.3. Profitability by Market Segments
            18.1.20.4. Sales Footprint
            18.1.20.5. Strategy Overview
                18.1.20.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Recommendations

Healthcare

RNA-Targeted Small Molecules Market

September 2024

REP-GB-13901

250 pages

Healthcare

DNA/RNA Extraction Market

June 2023

REP-GB-10543

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Antisense Oligonucleotides Market

Schedule a Call